Lundbeck (LUNDB DC) Q3 2026 (DKK): Revenue 6.6bln (exp. 6.33bln), adj. EBITDA 2.26bln (exp. 1.96bln). Raises FY guidance.

Lundbeck (LUNDB DC) Q3 2026 (DKK): Revenue 6.6bln (exp. 6.33bln), adj. EBITDA 2.26bln (exp. 1.96bln). Raises FY guidance.

A beat on both revenue and adjusted EBITDA accompanied by a guidance raise is the combination that has historically produced the most durable single-stock moves in European mid-cap pharma, since the raise converts one quarter of outperformance into a revised full-year base rather than a timing artefact. The questions that typically follow are the composition of the beat: whether it is driven by volume in the core CNS franchise or by pricing, one-off items, or cost phasing, and whether the guidance uplift is proportionate to the Q3 overshoot or deliberately conservative, a pattern this kind of issuer has often favoured. The peer read-through in specialty pharma tends to be limited, so the move usually stays idiosyncratic, concentrated in the equity and any associated credit rather than the sector. Worth watching is the call commentary on the growth drivers behind the raise, pipeline updates that reframe medium-term revenue visibility, and how sell-side models adjust, since the gap between the guidance raise and the magnitude of the beat is where the second-day trade has tended to be decided.